These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19999133)

  • 1. [Clinical efficacy of tolterodine for patients with overactive bladder after insufficient efficacy by monotherapy with alpha1-adrenoceptor antagonist].
    Tsujimura A; Takao T; Uchida K; Yamamoto K; Fukuhara S; Nakayama J; Ueda T; Hirai T; Kiuchi H; Miyagawa Y; Takahashi T; Kojimaan Y; Okuyama A
    Nihon Hinyokika Gakkai Zasshi; 2009 Nov; 100(7):686-92. PubMed ID: 19999133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.
    Höfner K; Burkart M; Jacob G; Jonas U
    World J Urol; 2010 Jun; 28(3):353-7. PubMed ID: 19997921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration.
    Chapple CR; Herschorn S; Abrams P; Wang JT; Brodsky M; Guan Z
    BJU Int; 2010 Nov; 106(9):1332-8. PubMed ID: 20497416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.
    Höfner K; Burkart M; Jacob G; Jonas U
    World J Urol; 2007 Dec; 25(6):627-33. PubMed ID: 17906864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
    Wang YY; Shi GW; He JY; Zhang YB
    Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1099-102. PubMed ID: 24432622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia.
    Chung SD; Chang HC; Chiu B; Liao CH; Kuo HC
    Neurourol Urodyn; 2011 Apr; 30(4):568-71. PubMed ID: 21344494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*.
    Herschorn S; Heesakkers J; Castro-Diaz D; Wang JT; Brodsky M; Guan Z;
    Curr Med Res Opin; 2008 Dec; 24(12):3513-21. PubMed ID: 19032133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.
    Chung DE; Te AE; Staskin DR; Kaplan SA
    Urology; 2010 May; 75(5):1144-8. PubMed ID: 20206978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
    Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
    BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study.
    Athanasopoulos A; Gyftopoulos K; Giannitsas K; Fisfis J; Perimenis P; Barbalias G
    J Urol; 2003 Jun; 169(6):2253-6. PubMed ID: 12771763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.